Treatment of polycystic ovary syndrome with insulin-lowering agents
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Early diagnosis and therapy of the underlying insulin resistance of heritable polycystic ovary syndrome (PCOS), often manifested at menarche, facilitate the reduction and/or reversal of the reproductive and metabolic morbidity of PCOS, as well as reduce the risk factors for cardiovascular disease. PCOS is characterised by oligoamenorrhoea, clinical and biochemical hyperandrogenism, infertility, recurrent miscarriage, insulin resistance, hyperinsulinaemia, gestational diabetes, impaired glucose tolerance, Type 2 diabetes, morbid obesity, hypertension, hypofibrinolysis, hypertriglyceridaemia, low levels of high density lipoprotein-cholesterol and a sevenfold risk increase in cardiovascular disease. Insulin sensitising-lowering agents reduce insulin resistance and hyperinsulinaemia, reverse PCOS endocrinopathy and ameliorate the reproductive, metabolic and cardiovascular morbidity of the disorder. The largest literature on the subject discusses metformin. Improved pregnancy outcomes in women with PCOS receiving metformin may be attributed to its ability to reduce insulin resistance, hyperinsulinaemia and hypofibrinolytic plasminogen activator inhibitor activity by the enhancement of folliculogenesis and improvement of oocyte quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743 · cited 2×
“In obese women with and without PCOS, metformin reduces BMI, body fat percentage and leptin concentrations in women with PCOS, and reduces fasting serum insulin, testosterone and LH levels [78].”
BackgroundLillioja, S., Mott, D. M., Spraul, M., Ferraro, R., Foley, J. E., Ravussin, E., Knowler, W. C., Bennett, P. H., & Bogardus, C. (1993) · New England Journal of Medicine · doi:10.1056/nejm199312303292703 · Cited by 1,508
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257 · cited 1×
“The insulin resistance characteristic of PCOS is directly and causally related to gestational diabetes, IGT and ultimately, Type 2 diabetes (Figure 1) [10,49,77-81].”
BackgroundKiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921
Velazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865
Self-citationCarbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus
Butte, N. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.5.1256s · Cited by 826
Nestler, J. E., & Jakubowicz, D. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608293350902 · Cited by 743
Moghetti, P., Castello, R., Negri, C., Tosi, F., Perrone, F., Caputo, M., Zanolin, E., & Muggeo, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6293 · Cited by 660
Clark, A. M., Ledger, W., Galletly, C., Tomlinson, L., Blaney, F., Wang, X., & Norman, R. J. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135772 · Cited by 642
Pasquali, R., Gambineri, A., Biscotti, D., Vicennati, V., Gagliardi, L., Colitta, D., Fiorini, S., Cognigni, G. E., Filicori, M., & Morselli-Labate, A. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6738 · Cited by 635 · cited 2×
“There have subsequently been 38 open-label and/or placebo-controlled studies which have documented the effectiveness of metformin in reducing hyperinsulinaemia and improving or normalising the endocrinopathy of PCOS with resultant normalisation of menstrual cyclicity and restoration of ovulation in 30 – 90% of both ad…”
BackgroundInsulin resistance as a predictor of age-related diseases
Facchini, F. S., Hua, N., Abbasi, F., & Reaven, G. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7763 · Cited by 594
Carmina, E., & Lobo, R. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5803 · Cited by 528
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518
Ehrmann, D. A., Schneider, D. J., Sobel, B. E., Cavaghan, M. K., Imperial, J., Rosenfield, R. L., & Polonsky, K. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.7.4069 · Cited by 461
Long or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus
Solomon, C. G. (2001) · JAMA · doi:10.1001/jama.286.19.2421 · Cited by 362 · cited 1×
“In Type 2 diabetes, 82% of women have polycystic ovaries on ultrasound [84] and 27% of women with Type 2 diabetes have been shown to have PCOS [85].”
BackgroundNorman, R. J., Masters, L., Milner, C. R., Wang, J. X., & Davies, M. J. (2001) · Human Reproduction · doi:10.1093/humrep/16.9.1995 · Cited by 341
Birdsall, M. A., Farquhar, C. M., & White, H. D. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-1-199701010-00005 · Cited by 327
Glueck, C. J., Fontaine, R. N., Wang, P., Subbiah, M. T. R., Weber, K., Illig, E., Streicher, P., Sieve-Smith, L., Tracy, T. M., Lang, J. E., et al. (2001) · Metabolism · doi:10.1053/meta.2001.24192 · Cited by 188 · cited 3×
“In obese adolescent girls with fasting hyperinsulinaemia and a family history of Type 2 diabetes, metformin lowered BMI and leptin and improved insulin sensitivity [100].”
BackgroundInfluentialSelf-citationSensitization to Insulin Induces Ovulation in Nonobese Adolescents with Anovulatory Hyperandrogenism
Ibáñez, L., Valls, C., Ferrer, A., Marcos, M. V., Rodriguez-Hierro, F., & de Zegher, F. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7756 · Cited by 162 · cited 4×
“Because PCOS is first manifest around the time of menarche [8,49,50,105], early diagnosis of the underlying insulin resistance syndrome opens the door to primary prevention of atherothrombosis, Type 2 diabetes, morbid obesity, hypertension, clinical and biochemical hyperandrogenaemia, hypofibrinolysis, oligoamenorrhoe…”
BackgroundInfluentialMastorakos, G., Koliopoulos, C., & Creatsas, G. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)02993-x · Cited by 137
Fulghesu, A. M., Villa, P., Pavone, V., Guido, M., Apa, R., Caruso, A., Lanzone, A., Rossodivita, A., & Mancuso, S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.2.3727 · Cited by 128
Dahlgren, E., Landin, K., Krotkiewski, M., Holm, G., & Janson, P. O. (1998) · Human Reproduction · doi:10.1093/humrep/13.10.2706 · Cited by 118
Cited by
Obesity as disruptor of the female fertility
Silvestris, E., de Pergola, G., Rosania, R., & Loverro, G. (2018) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-018-0336-z · Cited by 664
Obesity and reproductive disorders in women
Pasquali, R. (2003) · Human Reproduction Update · doi:10.1093/humupd/dmg024 · Cited by 539
Glueck, C. J., Papanna, R., Wang, P., Goldenberg, N., & Sieve-Smith, L. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00104-5 · Cited by 399
Self-citationGambineri, A., Pelusi, C., Genghini, S., Morselli‐Labate, A. M., Cacciari, M., Pagotto, U., & Pasquali, R. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01973.x · Cited by 216
Fruzzetti, F., Perini, D., Russo, M., Bucci, F., & Gadducci, A. (2017) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1236078 · Cited by 135
Metadata
- Authors
- Wang, P., Streicher, P., & Glueck, C. J.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2002-08
- Volume
- 3
- Issue
- 8
- Pages
- 1177-1189
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W1975593644
- Cited by
- 62
- References
- 24
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.